Table 1.

Patient-, disease-, and transplantation-related characteristics

Characteristic of patients	N (%)
Number of patients	233
Number of centers	83
Age, median(range), years	55 (19 – 79)
18–40	12 (5)
41–60	157 (67)
>60	64 (27)
Gender
Male	151 (65)
Female	82 (35)
Karnofsky score
<90%	84 (36)
90–100%	135 (58)
Missing	14 (6)
Time from diagnosis to transplant (range), months	15 (2 – 305)
Constitutional symptoms prior to HCT
No	182 (78)
Yes	42 (18)
Missing	9 (4)
Circulating blasts in blood at HCT
Absent	132 (57)
≥1%	101 (43)
Spleen status at transplant
Spleen not palpable	52 (22)
Splenomegaly	113 (48)
Splenectomy	59 (25)
Missing	9 (4)
Cytogenetics prior to HCT
Not evaluable/missing	84(36)
Normal Karyotype	89 (38)
Abnormal	66 (28)
Unfavorable	30(13)
Other abnormalities	30 (13)
Hemoglobin at HCT
<100g/L	148(64)
≥100g/L	85 (36)
Platelet count at transplant (range), × 109/L	121 (5 – 1835)
Platelet count prior to transplant
<100 × 109/L	94 (40)
≥100 × 109/L	116 (50)
Missing	23 (10)
WBC count at transplant (range), × 109/L	6 (<1 – 431)
DIPSS at transplant
Low risk	27 (12)
Int-1	114 (49)
Int-2	86 (37)
High-risk	3 (1)
Missing	3 (1)
Graft type
Bone marrow	28 (12)
Peripheral blood	205 (88)
Donor type
HLA-identical sibling	79 (34)
Well-matched URD	104 (45)
Partially matched URD	40 (17)
Mismatched URD	10 (4)
D-R CMV status
+/+	72 (31)
+/−	26 (11)
−/+	55 (24)
−/−	60 (26)
Missing	20 (9)
Conditioning regimen
FluTBI-based	51 (22)
FluMel-based	65 (28)
FluBu-based	89 (38)
Others	28 (12)
ATG or alemtuzumab use
ATG	110 (47)
Alemtuzumab	13 (6)
GVHD prophylaxis
Tarcrolimus-based	105 (45)
Cyclosporine-based	124 (53)
Other GVHD prophylaxis	4 (2)
Year of transplant
1997–2001	26 (11)
2002–2006	116 (50)
2007–2010	91 (39)
Median follow-up of survivors, range, months	50 (3 – 134)